Role of monoclonal antibody drugs in the treatment of COVID-19.
TLDR
Evidence suggests that elevated cytokine levels, reflecting a hyperinflammatory response secondary to SARS-CoV-2 infection, are responsible for multi-organ damage in patients with COVID-19.Abstract:
Currently clinicians all around the world are experiencing a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical presentation of this pathology includes fever, dry cough, fatigue and acute respiratory distress syndrome that can lead to death infected patients. Current studies on coronavirus disease 2019 (COVID-19) continue to highlight the urgent need for an effective therapy. Numerous therapeutic strategies have been used until now but, to date, there is no specific effective treatment for SARS-CoV-2 infection. Elevated inflammatory cytokines have been reported in patients with COVID-19. Evidence suggests that elevated cytokine levels, reflecting a hyperinflammatory response secondary to SARS-CoV-2 infection, are responsible for multi-organ damage in patients with COVID-19. For these reason, numerous randomized clinical trials are currently underway to explore the effectiveness of biopharmaceutical drugs, such as, interleukin-1 blockers, interleukin-6 inhibitors, Janus kinase inhibitors, in COVID-19. The aim of the present paper is to briefly summarize the pathogenetic rationale and the state of the art of therapeutic strategy blocking hyperinflammation.read more
Citations
More filters
Journal ArticleDOI
Dysregulated Interferon Response Underlying Severe COVID-19.
TL;DR: Current studies call for a better understanding of the IFN response regarding the spatiotemporal determination and subtype-specificity against SARS-CoV-2 infections, which are warranted to devise IFN-related prophylactics and therapies.
Journal ArticleDOI
IL-1 Receptor Antagonist Anakinra in the Treatment of COVID-19 Acute Respiratory Distress Syndrome: A Retrospective, Observational Study.
Marco Franzetti,Andrea Forastieri,Noemi Borsa,Alessandro Pandolfo,Chiara Molteni,Luca Borghesi,Silvia Pontiggia,Giulia Evasi,Lorenzo Guiotto,Mattia Erba,Ugo Pozzetti,Anna Ronchetti,Letizia Valsecchi,Gioacchino Castaldo,Ernesto Longoni,Daniele Colombo,Marco Soncini,Stefano Crespi,Stefano Maggiolini,Davide Guzzon,Stefania Piconi +20 more
TL;DR: In this paper, the IL-1 receptor antagonist, anakinra, may represent a therapeutic option for acute respiratory distress syndrome (ARDS) associated with coronavirus disease 2019 (COVID-19).
Journal ArticleDOI
Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants
Jianguo Jin,Chengcheng Li,Chunhong Ye,Zhihui Ruan,Yicong Liang,Yongkui Li,Jianguo Wu,Zhen Luo +7 more
TL;DR: Wang et al. as discussed by the authors systematically summarized two main therapeutic strategies against the coronavirus disease 2019 (COVID-19) pandemic, namely drugs targeting the SARS-CoV-2 life cycle, and drugs targeting SARS CoV2 induced inflammation in host cells.
Journal ArticleDOI
Mediterranean Diet for the Prevention of Gestational Diabetes in the Covid-19 Era: Implications of Il-6 In Diabesity.
Anna Lucia Fedullo,Antonio Schiattarella,Maddalena Morlando,Anna Raguzzini,Elisabetta Toti,Pasquale De Franciscis,Ilaria Peluso +6 more
TL;DR: In this paper, the influence of Mediterranean Diet on Gestational Diabetes Mellitus (GDM) and Gestational Weight Gain (GWG) during the COVID-19 pandemic era and the specific role of interleukin (IL)-6 in diabesity.
Journal ArticleDOI
Alterations in Circulating Monocytes Predict COVID-19 Severity and Include Chromatin Modifications Still Detectable Six Months after Recovery.
Alberto Utrero-Rico,Cecilia González-Cuadrado,Marta Chivite-Lacaba,Oscar Cabrera-Marante,Rocío Laguna-Goya,Patricia Almendro-Vázquez,Carmen Díaz-Pedroche,María Ruiz-Ruigómez,Antonio Lalueza,María Dolores Folgueira,Enrique Vázquez,Ana Quintas,Marcos J. Berges-Buxeda,Moisés Martín-Rodriguez,Ana Dopazo,Antonio Serrano-Hernández,José María Aguado,Estela Paz-Artal +17 more
TL;DR: In this article, an early analysis of circulating monocytes may be critical for predicting COVID-19 course and its sequelae, and they showed decreased surface molecule expression, including low HLA-DR, in association with an inflammatory cytokine status and limited antiSARS-CoV-2-specific T cell response.
References
More filters
Journal ArticleDOI
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.
Zhe Xu,Lei Shi,Yijin Wang,Ji-Yuan Zhang,Lei Huang,Chao Zhang,Shuhong Liu,Peng Zhao,Hongxia Liu,Li Zhu,Yanhong Tai,Changqing Bai,Tingting Gao,Jin-Wen Song,Peng Xia,Jing-Hui Dong,Jingmin Zhao,Fu-Sheng Wang +17 more
TL;DR: O surto do novo coronavÃrus (COVID-19) em Wuhan, China, iniciado em dezembro de 2019, evoluiu para se tornar uma pandemia global A.
Journal ArticleDOI
The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak.
TL;DR: The symptoms, epidemiology, transmission, pathogenesis, phylogenetic analysis and future directions to control the spread of this fatal disease are highlighted.
Journal ArticleDOI
Emerging coronaviruses: Genome structure, replication, and pathogenesis.
Yu Chen,Qianyun Liu,Deyin Guo +2 more
TL;DR: This review will help understand the biology and potential risk of CoVs that exist in richness in wildlife such as bats and describe diseases caused by different CoVs in humans and animals.
Journal ArticleDOI
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
TL;DR: This review summarizes acute and chronic inflammatory diseases that are treated by reducing IL-1β activity and proposes that disease severity is affected by the anti-inflammatory members of the IL- 1 family of ligands and receptors.
Journal ArticleDOI
Tocilizumab treatment in COVID-19: A single center experience.
TL;DR: TCZ appears to be an effective treatment option in COVID‐19 patients with a risk of cytokine storms and for these critically ill patients with elevated IL‐6, the repeated dose of the TCZ is recommended.